Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,024.09 USD
-20.57 (-1.97%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $1,023.90 -0.19 (-0.02%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
REGN 1,024.09 -20.57(-1.97%)
Will REGN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roche (RHHBY) Gets Positive CHMP Recommendation for Its Drugs
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Other News for REGN
EU approves Sanofi drug Dupixent for chronic lung disease
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
IN BRIEF: Regeneron's odronextamab recommended for European approval
What's Going On With Regeneron Pharmaceuticals Stock On Friday?
Regeneron lymphoma antibody drug endorsed for conditional approval in EU